Metformin Effects on Prostate Cancer Risk and Outcomes

Metformin, a first-line therapy for type 2 diabetes, has attracted attention for its potential impact on prostate cancer risk and progression. Epidemiological data suggest a modest inverse association between metformin use and prostate cancer incidence, though findings have varied across studies. Preclinical investigations attribute this to both direct tumour-suppressive mechanisms—such as activation of energy-sensing pathways, inhibition of protein synthesis and induction of apoptosis—and indirect effects arising from improved metabolic control. Clinically, metformin has been assessed as an adjunct to standard therapies, with emerging evidence that it may enhance responses to androgen deprivation and delay disease recurrence. However, heterogeneity in patient populations, treatment regimens and study designs continues to challenge firm conclusions. Given metformin’s global availability, low cost and established safety, clarifying its role in prostate cancer management carries significant public health implications.

Research from Nature Portfolio

A comprehensive meta-analysis pooling data from more than 1.6 million patients has refined our understanding of metformin’s dual effects. Although metformin use did not reduce the incidence of prostate cancer, it was consistently linked with improved survival outcomes in men already diagnosed with the disease. In particular, metformin treatment was associated with longer overall survival, enhanced cancer-specific survival and extended recurrence-free survival compared with non-use. These findings reinforce the notion that metformin may serve as a valuable adjuvant, improving patient prognosis without altering rates of new tumour development.

Metformin Effects on Prostate Cancer Risk and Outcomes publication trend

The graph below shows the total number of articles in metformin effects on prostate cancer risk and outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Overall survival (OS): The length of time from the start of treatment until death from any cause.

Cancer-specific survival (CSS): The period from diagnosis or treatment initiation until death attributable specifically to prostate cancer.

Recurrence-free survival (RFS): The interval during which a patient remains free of detectable cancer following initial therapy.

Adenosine monophosphate-activated protein kinase (AMPK): A cellular energy sensor that, when activated, inhibits anabolic processes and can suppress tumour growth.

Super-enhancer: A large cluster of regulatory DNA elements that drives high-level expression of genes critical to cell identity or disease processes, including those involved in drug resistance.

References

1. Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer. Signal Transduction and Targeted Therapy (2023).
2. The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis. Scientific Reports (2019).
3. Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences (2020).
4. Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies. PLOS ONE (2014).